A phase II  clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma

ConclusionThese results suggest future studies are warranted to further evaluate the clinical efficacy of GPX ‐150 in STS, perhaps at doses higher than 265 mg/m2.

Source: Cancer Medicine - April 22, 2019 Category: Cancer & Oncology Authors: Brian A. Van Tine, Mark Agulnik, Richard D. Olson, Gerald M. Walsh, Arthur Klausner, Nicole E. Frank, Todd T. Talley, Mohammed M. Milhem Tags: ORIGINAL ARTICLE Source Type: research